Detailed explanation of possible adverse reactions caused by Fidanaco-Ella Parvowitz gene therapy

Fidanacogene elaparvovec (fidanacogene elaparvovec) gene therapy is a new treatment for hemophilia B. Although it has significant efficacy, it may still be accompanied by a series of side effects.

1. Side effects related to immune response

This therapy uses adeno-associated virus (AAV) as a vector to introduce the coagulation factor IX gene into the patient's liver cells. However, some patients may develop an immune response to the AAV vector, leading to hepatotoxicity, neurotoxicity and other side effects. Although such serious side effects are rare in clinical trials, patients' liver function, neurological symptoms and other indicators still need to be closely monitored in order to detect and deal with potential risks in a timely manner.

2. Risks related to gene integration

The core mechanism of gene therapy is to integrate exogenous genes into the host cell genome. Although this therapy uses a single-dose model, the random nature of gene integration may cause insertional mutations, which may affect the normal function of oncogenes or tumor suppressor genes. Although there is currently no clear evidence that this therapy directly causes tumors, the long-term safety still needs to be further verified through large-scale, long-term follow-up studies.

3. Other potential side effects

Clinical trial data show that some patients may experience short-term side effects such as injection site reactions (such as pain, redness and swelling), fever, and headache. In addition, because gene therapy may affect the body's immune system function, a small number of patients may experience non-specific manifestations such as increased risk of infection and abnormal coagulation function.

4. The Importance of Patient Screening and Monitoring

To reduce the risk of side effects, this therapy is strictly limited to adults with moderate to severe B hemophilia who are 18 years old and above and do not have neutralizing antibodies against the AAVRh74var capsid. Before treatment, patients must be confirmed to be eligible through an FDA-approved test. After treatment, long-term follow-up is required to evaluate coagulation factor IX expression levels, bleeding events and potential side effects.

Reference materials:https://en.wikipedia.org/wiki/Fidanacogene_elaparvovec